ArticleTissue engineering. Part A2014
White paper on how to go forward with cell-based advanced therapies in Europe.
Article in Tissue engineering. Part A, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells.Stem cell research & therapy · 2022Article
- Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia.International journal of molecular sciences · 2020Review
- Article
- Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.Journal of translational medicine · 2018Article
- Tracking mesenchymal stem cell contributions to regeneration in an immunocompetent cartilage regeneration model.JCI insight · 2017Article
- Cellular Therapies for Treatment of Radiation Injury: Report from a NIH/NIAID and IRSN Workshop.Radiation research · 2017Article
- Healing of a Large Long-Bone Defect through Serum-Free In Vitro Priming of Human Periosteum-Derived Cells.Stem cell reports · 2017Article
- A 3D ex vivo mandible slice system for longitudinal culturing of transplanted dental pulp progenitor cells.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2015Article
- Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP).Journal of translational medicine · 2015Article
- A case for crowd sourcing in stem cell research.Stem cells translational medicine · 2014Article
- Skeletal tissue regeneration: where can hydrogels play a role?International orthopaedics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current White paper summarizes the discussions and exchange of experiences during the first European Interdisciplinary Summit on Cell-Based ATMPs held in Vienna, Austria, May 02-03, 2013. The meeting was supported by the Research Networking Programme REMEDIC (regenerative medicine) funded by the European Science Foundation and by the British Medical Research Council. To improve the competitiveness of Europe in the field of cell-based Advanced Medicinal Therapy Products (ATMPs), the following key issues were identified during the meeting: removal of national hurdles in the European Union, harmonization of national and subnational differences in Hospital Exemption rules, improved treatment algorithms for reimbursement, better knowledge on the mode of action, predictive preclinical efficacy and safety testing, need for innovative systems for preclinical testing, appropriate product characterization, manufacturing with cost of goods in mind, and appropriate design of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.